

# Dimitrios T Boumpas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7091120/publications.pdf>

Version: 2024-02-01

225  
papers

19,569  
citations

18436

62  
h-index

11899

134  
g-index

227  
all docs

227  
docs citations

227  
times ranked

19719  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
2	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
3	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
4	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
5	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
6	Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates. <i>Annals of Internal Medicine</i> , 1993, 119, 1198.	2.0	646
7	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
8	A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 719-727.	6.7	546
9	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.5	463
10	Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide Therapy. <i>Annals of Internal Medicine</i> , 1993, 119, 366.	2.0	449
11	Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis. <i>Annals of Internal Medicine</i> , 2001, 135, 248.	2.0	417
12	Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. <i>Kidney International</i> , 1994, 45, 544-550.	2.6	348
13	Neutrophil Extracellular Trap Formation Is Associated with IL-1 <sup>β</sup> and Autophagy-Related Signaling in Gout. <i>PLoS ONE</i> , 2011, 6, e29318.	1.1	333
14	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2018, 379, 2209-2219.	13.9	326
15	Update in the diagnosis and management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 14-25.	0.5	312
16	Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1496-1506.	0.5	276
17	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
18	Neutrophil extracellular traps promote differentiation and function of fibroblasts. <i>Journal of Pathology</i> , 2014, 233, 294-307.	2.1	262

#	ARTICLE	IF	CITATIONS
19	Systemic Lupus Erythematosus: Emerging Concepts: Part 1: Renal, Neuropsychiatric, Cardiovascular, Pulmonary, and Hematologic Disease. <i>Annals of Internal Medicine</i> , 1995, 122, 940.	2.0	260
20	Thyroid Dysfunction and Autoantibodies in Early Pregnancy Are Associated with Increased Risk of Gestational Diabetes and Adverse Birth Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4464-4472.	1.8	234
21	Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor- $\alpha$ antibody therapy. <i>Blood</i> , 2002, 100, 474-482.	0.6	232
22	Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1854-1863.	0.5	229
23	Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. <i>Nature Reviews Rheumatology</i> , 2010, 6, 358-367.	3.5	218
24	Crucial Role of Granulocytic Myeloid-Derived Suppressor Cells in the Regulation of Central Nervous System Autoimmune Disease. <i>Journal of Immunology</i> , 2012, 188, 1136-1146.	0.4	216
25	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.5	203
26	<i>Aspergillus</i> Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. <i>Cell Host and Microbe</i> , 2016, 19, 79-90.	5.1	183
27	Does rituximab increase the incidence of infectious complications? A narrative review. <i>International Journal of Infectious Diseases</i> , 2011, 15, e2-e16.	1.5	178
28	REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 238-248.	0.5	153
29	Major peptide autoepitopes for nucleosome-specific T cells of human lupus. <i>Journal of Clinical Investigation</i> , 1999, 104, 345-355.	3.9	153
30	Systemic Lupus Erythematosus: Emerging Concepts: Part 2: Dermatologic and Joint Disease, the Antiphospholipid Antibody Syndrome, Pregnancy and Hormonal Therapy, Morbidity and Mortality, and Pathogenesis. <i>Annals of Internal Medicine</i> , 1995, 123, 42.	2.0	151
31	Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1992, 35, 259-269.	6.7	139
32	Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor $\alpha$ -mediated effect. <i>Blood</i> , 2002, 99, 1610-1619.	0.6	138
33	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.5	128
34	The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1870-1880.	6.7	126
35	Corticosteroids Block Autophagy Protein Recruitment in <i>Aspergillus fumigatus</i> Phagosomes via Targeting Dectin-1/Syk Kinase Signaling. <i>Journal of Immunology</i> , 2013, 191, 1287-1299.	0.4	124
36	Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1603-1611.	0.5	121

#	ARTICLE	IF	CITATIONS
37	An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. <i>Autoimmunity Reviews</i> , 2019, 18, 751-760.	2.5	115
38	IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis. <i>Journal of Immunology</i> , 2001, 167, 4075-4082.	0.4	113
39	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1079-1089.	0.5	109
40	Intermittent Cyclophosphamide for the Treatment of Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 1990, 112, 674.	2.0	106
41	Diagnostic criteria for systemic lupus erythematosus: has the time come?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 687-694.	3.5	103
42	Toll like receptors and autoimmunity: A critical appraisal. <i>Journal of Autoimmunity</i> , 2007, 29, 310-318.	3.0	101
43	Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 207-218.	6.7	99
44	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.4	97
45	IFN $\gamma$ Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. <i>Cell Reports</i> , 2018, 25, 921-933.e5.	2.9	97
46	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
47	Neutrophil extracellular traps regulate IL-1 $\beta$ -mediated inflammation in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 269-277.	0.5	94
48	Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. <i>Human Immunology</i> , 1999, 60, 479-491.	1.2	93
49	Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. <i>Journal of Clinical Investigation</i> , 2017, 127, 2789-2804.	3.9	92
50	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581.	1.5	91
51	Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. <i>Journal of Rheumatology</i> , 2006, 33, 2440-6.	1.0	88
52	Distinct T Cell/Renal Tubular Epithelial Cell Interactions Define Differential Chemokine Production: Implications for Tubulointerstitial Injury in Chronic Glomerulonephritides. <i>Journal of Immunology</i> , 2000, 164, 3323-3329.	0.4	84
53	Fungal infections complicating tumor necrosis factor alpha blockade therapy. <i>Mayo Clinic Proceedings</i> , 2008, 83, 181-94.	1.4	84
54	Increased apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. <i>British Journal of Haematology</i> , 2001, 115, 167-174.	1.2	83

#	ARTICLE	IF	CITATIONS
55	An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion. <i>Nature Immunology</i> , 2020, 21, 75-85.	7.0	82
56	Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 447-457.	1.6	80
57	Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity. <i>Cell Metabolism</i> , 2020, 32, 591-604.e7.	7.2	79
58	Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous population. <i>Human Immunology</i> , 2008, 69, 567-571.	1.2	75
59	Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1548-1553.	0.5	75
60	Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation. <i>European Journal of Immunology</i> , 2016, 46, 2542-2554.	1.6	75
61	REGULATION OF TRANSFORMING GROWTH FACTOR- $\beta$ 1 AND ITS RECEPTOR BY CYCLOSPORINE IN HUMAN T LYMPHOCYTES. <i>Transplantation</i> , 1995, 60, 718-723.	0.5	74
62	In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 232-241.	0.5	71
63	Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1992-2000.	0.5	68
64	Increased Frequency of Mutations in the Gene Responsible for Familial Mediterranean Fever (MEFV) in a Cohort of Patients with Ulcerative Colitis: Evidence for a Potential Disease-Modifying Effect?. <i>Digestive Diseases and Sciences</i> , 2006, 51, 687-692.	1.1	67
65	Anti-Citrulline Antibodies in the Diagnosis and Prognosis of Rheumatoid Arthritis: Evolving Concepts. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2007, 44, 339-363.	2.7	63
66	Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. <i>Lupus</i> , 2009, 18, 831-835.	0.8	62
67	Gene expression in systemic lupus erythematosus: Bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. <i>Arthritis and Rheumatism</i> , 2008, 58, 3541-3549.	6.7	61
68	Low disease activity irrespective of serologic status at baseline associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	1.6	59
69	The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21. <i>European Journal of Immunology</i> , 2011, 41, 1754-1763.	1.6	57
70	STAT4: A risk factor for type 1 diabetes?. <i>Human Immunology</i> , 2008, 69, 647-650.	1.2	56
71	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2184-2190.	0.5	53
72	Innate immunity in systemic lupus erythematosus: Sensing endogenous nucleic acids. <i>Journal of Autoimmunity</i> , 2010, 35, 206-211.	3.0	52

#	ARTICLE	IF	CITATIONS
73	Gene expression and regulation in systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1084-1096.	1.7	52
74	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	1.1	51
75	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.5	51
76	Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 758-766.	0.5	50
77	The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 696-699.	0.5	49
78	Programmed Death-1 Shapes Memory Phenotype CD8 T Cell Subsets in a Cell-Intrinsic Manner. <i>Journal of Immunology</i> , 2013, 190, 6104-6114.	0.4	49
79	Pathogenesis and treatment of CNS lupus. <i>Current Opinion in Rheumatology</i> , 2013, 25, 577-583.	2.0	49
80	EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. <i>Rheumatology</i> , 2015, 54, 1270-1278.	0.9	48
81	Sexual dimorphism in SLE: above and beyond sex hormones. <i>Lupus</i> , 2019, 28, 3-10.	0.8	48
82	Genetic justification of severe COVID-19 using a rigorous algorithm. <i>Clinical Immunology</i> , 2021, 226, 108726.	1.4	47
83	High-Density Lipoprotein Attenuates Th1 and Th17 Autoimmune Responses by Modulating Dendritic Cell Maturation and Function. <i>Journal of Immunology</i> , 2015, 194, 4676-4687.	0.4	46
84	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
85	Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19. <i>Food and Chemical Toxicology</i> , 2020, 145, 111694.	1.8	45
86	TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. <i>Human Immunology</i> , 2011, 72, 1210-1213.	1.2	44
87	Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Linked to Reactive Oxygen Species-Dependent Extracellular Trap Formation. <i>Arthritis and Rheumatology</i> , 2016, 68, 449-461.	2.9	44
88	Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 242-253.	0.5	44
89	Intestinal ischemia as the first manifestation of vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 431-441.	1.6	43
90	Spinal infections: evolving concepts. <i>Current Opinion in Rheumatology</i> , 2008, 20, 471-479.	2.0	43

#	ARTICLE	IF	CITATIONS
91	Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. <i>Journal of Rheumatology</i> , 2018, 45, 785-794.	1.0	43
92	Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 441-448.	0.5	43
93	Vasculitis associated with primary rheumatologic diseases. <i>Current Opinion in Rheumatology</i> , 1998, 10, 58-65.	2.0	42
94	Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. <i>Clinical Rheumatology</i> , 2007, 26, 1044-1048.	1.0	42
95	Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. <i>Clinical Research in Cardiology</i> , 2019, 108, 1093-1101.	1.5	41
96	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. <i>RMD Open</i> , 2020, 6, e001263.	1.8	39
97	Update on the management of lupus nephritis: let the treatment fit the patient. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 464-472.	3.2	38
98	Elevated interleukin-10: A new cause of dyslipidemia leading to severe HDL deficiency. <i>Journal of Clinical Lipidology</i> , 2015, 9, 81-90.	0.6	38
99	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
100	Autoimmune hepatitis: evolving concepts. <i>Autoimmunity Reviews</i> , 2004, 3, 207-214.	2.5	36
101	Prostaglandin E2 Inhibits the Nuclear Transcription of the Human Interleukin 2, but Not the IL-4, Gene in Human T Cells by Targeting Transcription Factors AP-1 and NF-AT. <i>Cellular Immunology</i> , 1996, 171, 95-101.	1.4	35
102	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
103	Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study. <i>Dermatologic Therapy</i> , 2019, 32, e13006.	0.8	34
104	Gene Network Analysis of Bone Marrow Mononuclear Cells Reveals Activation of Multiple Kinase Pathways in Human Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2010, 5, e13351.	1.1	33
105	In Vivo Ablation of Plasmacytoid Dendritic Cells Inhibits Autoimmunity through Expansion of Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2013, 190, 2631-2640.	0.4	33
106	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 7-15.	0.3	33
107	Human Platelets Stimulate Mesangial Cells to Produce Monocyte Chemoattractant Protein-1 via the CD40/CD40 Ligand Pathway and May Amplify Glomerular Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2488-2496.	3.0	31
108	NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN- $\gamma$ production in patients with SLE. <i>JCI Insight</i> , 2021, 6, .	2.3	28

#	ARTICLE	IF	CITATIONS
109	Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans. <i>PLoS ONE</i> , 2013, 8, e66456.	1.1	27
110	Coexistence of systemic lupus erythematosus and multiple sclerosis: Prevalence, clinical characteristics, and natural history. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 751-758.	1.6	26
111	Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 22-30.	3.2	25
112	Intron 4 a/b polymorphism of the endothelial nitric oxide synthase gene is associated with both type 1 and type 2 diabetes in a genetically homogeneous population. <i>Human Immunology</i> , 2008, 69, 279-283.	1.2	25
113	The Cretan Aging Cohort: Cohort Description and Burden of Dementia and Mild Cognitive Impairment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 23-33.	0.9	25
114	Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 107-17.	1.0	25
115	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 267.	1.6	24
116	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021, 60, 170-178.	0.9	24
117	Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 910-917.	0.4	24
118	Signal Requirements for Interleukin 4 Promoter Activation in Human T Cells. <i>Cellular Immunology</i> , 1996, 168, 33-38.	1.4	23
119	Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 887-890.	0.8	23
120	Differential Expression of miR-4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF). <i>Journal of Cellular Physiology</i> , 2017, 232, 1326-1336.	2.0	23
121	Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population. <i>PLoS ONE</i> , 2013, 8, e74375.	1.1	22
122	Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1676-1686.	0.4	22
123	Update on the pathogenesis of central nervous system lupus. <i>Current Opinion in Rheumatology</i> , 2019, 31, 669-677.	2.0	22
124	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review. <i>Hematological Oncology</i> , 2014, 32, 113-119.	0.8	21
125	GLUCOCORTICOIDS MODULATE CD28 MEDIATED PATHWAYS FOR INTERLEUKIN 2 PRODUCTION IN HUMAN T CELLS. <i>Transplantation</i> , 1996, 62, 1113-1118.	0.5	21
126	Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. <i>Clinical Immunology</i> , 2003, 106, 65-72.	1.4	19



#	ARTICLE	IF	CITATIONS
127	A CD40 and an NCOA5 gene polymorphism confer susceptibility to psoriasis in a Southern European population: A case-control study. <i>Human Immunology</i> , 2011, 72, 761-765.	1.2	19
128	Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. <i>Autoimmunity Reviews</i> , 2018, 17, 11-18.	2.5	19
129	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. <i>Cancer Immunology Research</i> , 2021, 9, 726-734.	1.6	19
130	Synovitis in angioimmunoblastic lymphadenopathy with dysproteinemia simulating rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 578-582.	6.7	18
131	Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. <i>Lupus Science and Medicine</i> , 2020, 7, e000394.	1.1	18
132	Fabrication of a 3D microfluidic cell culture device for bone marrow-on-a-chip. <i>Micro and Nano Engineering</i> , 2020, 9, 100075.	1.4	17
133	MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 996-1004.	1.6	17
134	Lupus nephritis. <i>Current Opinion in Rheumatology</i> , 1996, 8, 415-423.	2.0	16
135	Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2144-2150.	0.4	16
136	Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF- $\alpha$ agents. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 43-52.	0.4	16
137	Lupus nephritis "winning a few battles but not the war. <i>Nature Reviews Rheumatology</i> , 2011, 7, 441-442.	3.5	15
138	Transcriptional and post-transcriptional mechanisms are responsible for the increased expression of c-myc protooncogene in lymphocytes from patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 507-515.	2.1	14
139	A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2059-2061.	0.5	14
140	Cyclophosphamide and Lupus Nephritis: When, How, For How Long?. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 181-191.	2.9	14
141	Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or "blood-dominant" lupus?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 683-684.	0.5	14
142	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 27-37.	0.3	13
143	Human T-cell leukemia/lymphoma virus I and/or Epstein-Barr virus-infected B-cell lines spontaneously produce acid-labile $\gamma$ -interferon. <i>Journal of Clinical Immunology</i> , 1985, 5, 340-344.	2.0	12
144	Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2020, 7, 288.	1.2	12

#	ARTICLE	IF	CITATIONS
145	C-MYC proto-oncogene expression in peripheral blood mononuclear cells from patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1990, 33, 49-56.	6.7	11
146	Perspective on future therapy of vasculitis. <i>Current Rheumatology Reports</i> , 2000, 2, 423-429.	2.1	11
147	Dysregulated production of interleukin-1 <sup>β</sup> upon activation of the NLRP3 inflammasome in patients with familial Mediterranean fever. <i>Human Immunology</i> , 2015, 76, 488-495.	1.2	11
148	Imaging Risk in Multisystem Inflammatory Diseases. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2517-2537.	2.3	11
149	Hydroxychloroquine dosing in systemic lupus erythematosus: response to a Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis <i>et al</i> by Costedoat-Chalumeau <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e91-e91.	0.5	11
150	How does the joint dermatology/rheumatology clinic benefit both patients and dermatologists?. <i>Dermatologic Therapy</i> , 2020, 33, e13283.	0.8	11
151	Interstitial Pneumonia with Autoimmune Features (IPAF): A Single-Centre, Prospective Study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 330.	0.3	11
152	Tpl2 kinase regulates Fc $\gamma$ R signaling and immune thrombocytopenia in mice. <i>Journal of Leukocyte Biology</i> , 2013, 94, 751-757.	1.5	10
153	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093713.	1.2	10
154	Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
155	2008-2018: a decade of recommendations for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1547-1548.	0.5	9
156	Geoeidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients' data. <i>Turkish Journal of Medical Sciences</i> , 2020, 44, 281-290.	0.4	9
157	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
158	Cholera toxin promotes the proliferation of anti- $\alpha$ antibody-prestimulated human B cells. <i>Cellular Immunology</i> , 1992, 140, 237-247.	1.4	8
159	Urine proteomics for the early diagnosis of acute glomerulonephritis: Has the time come?. <i>Arthritis and Rheumatism</i> , 2007, 56, 705-709.	6.7	8
160	Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2020, 10, 16648.	1.6	8
161	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2223-2230.	0.9	8
162	Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the Attikon Lupus Cohort. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	8

#	ARTICLE	IF	CITATIONS
163	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.4	7
164	The role of the pro-apoptotic protein Siva in the pathogenesis of Familial Mediterranean fever: A structural and functional analysis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 402, 141-146.	1.0	6
165	Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece. <i>PLoS ONE</i> , 2019, 14, e0226287.	1.1	6
166	Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. <i>Rheumatology</i> , 2021, 60, 4166-4174.	0.9	6
167	DNA Damage Response in the Adaptive Arm of the Immune System: Implications for Autoimmunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5842.	1.8	6
168	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. <i>American Journal of Medicine</i> , 2022, 135, 244-253.e3.	0.6	6
169	Patrolling human SLE haematopoietic progenitors demonstrate enhanced extramedullary colonisation; implications for peripheral tissue injury. <i>Scientific Reports</i> , 2021, 11, 15759.	1.6	5
170	Unraveling the complexities of psoriatic arthritis by the use of -Omics and their relevance for clinical care. <i>Autoimmunity Reviews</i> , 2021, 20, 102949.	2.5	5
171	Treatment of lupus: more options after a long wait. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 753-756.	0.5	5
172	Sequential therapies with intravenous cyclophosphamide and oral mycophenolate mofetil or azathioprine are efficacious and safe in proliferative lupus nephritis. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, 276-7.	0.4	5
173	Cerebral Lupus Erythematosus. <i>CNS Drugs</i> , 1995, 3, 416-426.	2.7	4
174	Enhanced release of neutrophil extracellular traps from peripheral blood neutrophils in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A79.2-A79.	0.5	4
175	Self-reported fatigue as a risk index for dementia diagnosis. <i>European Geriatric Medicine</i> , 2018, 9, 211-217.	1.2	4
176	Cognitive Impairment and Dementia in Primary Care: Current Knowledge and Future Directions Based on Findings From a Large Cross-Sectional Study in Crete, Greece. <i>Frontiers in Medicine</i> , 2020, 7, 592924.	1.2	4
177	Converging evidence of impaired brain function in systemic lupus erythematosus: changes in perfusion dynamics and intrinsic functional connectivity. <i>Neuroradiology</i> , 2022, 64, 1593-1604.	1.1	4
178	Pharmacotherapy of lupus nephritis: time for a consensus?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2099-2115.	0.9	3
179	Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 437-451.	1.3	3
180	Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 73.	1.0	3

#	ARTICLE	IF	CITATIONS
181	Life-threatening antineutrophil cytoplasmic antibody-associated vasculitis after influenza A H1N1 infection requiring veno-venous extracorporeal membrane oxygenation. <i>Perfusion (United Kingdom)</i> , 2020, 35, 546-549.	0.5	3
182	Recent progress in the treatment of lupus nephritis. <i>Modern Rheumatology</i> , 2012, 22, 803-813.	0.9	3
183	Development of an ANCA-Associated Vasculitides Patient Registry in Greece. <i>Mediterranean Journal of Rheumatology</i> , 2019, 31, 84.	0.3	3
184	Performance of the systemic lupus erythematosus risk probability index in a cohort of undifferentiated connective tissue disease. <i>Rheumatology</i> , 2022, 61, 3606-3613.	0.9	3
185	Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 999-1005.	0.4	3
186	In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 806-813.	0.4	3
187	From first symptoms to diagnosis of systemic lupus erythematosus: mapping the journey of patients in an observational study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	3
188	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 569-570.	0.5	2
189	What's new in clinical trials in lupus?. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 473-485.	0.3	2
190	Almost Half of Octogenarians and Nonagenarians Admitted Acutely to Internal Medicine Ward Die During Admission or Within 6 Months After Discharge: Time to Redefine Treatment Goals?. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 380-383.	1.3	2
191	Cognitive impairment in a primary healthcare population: a cross-sectional study on the island of Crete, Greece. <i>BMJ Open</i> , 2020, 10, e035551.	0.8	2
192	Advances in Systemic Lupus Erythematosus (SLE): A case for optimism. <i>Mediterranean Journal of Rheumatology</i> , 2017, 28, 1-3.	0.3	2
193	Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 103-105.	0.3	2
194	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. <i>Mediterranean Journal of Rheumatology</i> , 2019, 31, 87.	0.3	2
195	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A14-A14.	0.5	1
196	Correction: Crucial Role of Granulocytic Myeloid-Derived Suppressor Cells in the Regulation of Central Nervous System Autoimmune Disease. <i>Journal of Immunology</i> , 2014, 192, 1334-1334.	0.4	1
197	Aseptic abscess syndrome associated with traveler's diarrhea after a trip to Malaysia. <i>IDCases</i> , 2016, 6, 23-25.	0.4	1
198	FP098REDD1/AUTOPHAGY PATHWAY PROMOTES THROMBOINFLAMMATION AND FIBROSIS IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) BY THE RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS). <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i80-i80.	0.4	1

#	ARTICLE	IF	CITATIONS
199	THU0254â€¦TRENDS OF SEVERITY, PROGRESSION AND BURDEN OF DISEASE IN THE â€œATTIKONâ€•SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) COHORT: EVIDENCE FOR THE RULE OF â€œONE THIRDâ€•IN DISEASE SEVERITY. , 2019, , .		1
200	Response to: â€™Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki<i>et al'</i> by Wallace. Annals of the Rheumatic Diseases, 2019, 78, e6-e6.	0.5	1
201	Response to: â€™Treatment of systemic lupus erythematosus: donâ€™t forget hydroxychloroquineâ€™™ by Michaud <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e134-e134.	0.5	1
202	Response to: â€™Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosusâ€™™ by Rua-Figueroa and Erasquin. Annals of the Rheumatic Diseases, 2020, 79, e132-e132.	0.5	1
203	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteriaâ€”documenting progress in lupus. Rheumatology, 2020, 60, 2976-2978.	0.9	1
204	Response to: â€™Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendationsâ€™™ by Orsolini et al. Annals of the Rheumatic Diseases, 2020, 79, e151-e151.	0.5	1
205	Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs. Mediterranean Journal of Rheumatology, 2017, 28, 164-168.	0.3	1
206	Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study. Mediterranean Journal of Rheumatology, 2018, 29, 236-239.	0.3	1
207	2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists. Mediterranean Journal of Rheumatology, 2019, 30, 82.	0.3	1
208	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 163.	0.3	1
209	Long-Term Outcome in Lupus Nephritis. Annals of Internal Medicine, 2002, 137, 545.	2.0	0
210	Therapeutic strategies for refractory systemic lupus erythematosus. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 375-382.	0.5	0
211	An update on the management of comorbid conditions in lupus nephritis. Clinical Investigation, 2013, 3, 281-293.	0.0	0
212	A5.26â€¦Regulation of Expression and Function of Negative Immunomodulatory Receptors in B-Cells: Implications for the Pathogenesis of Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2013, 72, A40.1-A40.	0.5	0
213	Correction: In Vivo Ablation of Plasmacytoid Dendritic Cells Inhibits Autoimmunity through Expansion of Myeloid-Derived Suppressor Cells. Journal of Immunology, 2014, 192, 1332-1332.	0.4	0
214	03.23â€¦Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy. , 2017, , .		0
215	FRI0444â€¦EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS FOLLOWING INADEQUATE RESPONSE TO SYNTHETIC OR BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN REAL-LIFE SETTINGS. , 2019, , .		0
216	SAT0247â€¦FEMALE SEX AND AGE AT DIAGNOSIS ARE ASSOCIATED WITH A DECREASED POSSIBILITY OF DRUG DISCONTINUATION IN GIANT CELL ARTERITIS: DATA FROM A MULTICENTER PROSPECTIVE COHORT OF 177 PATIENTS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
217	P0359CROSS-TISSUE AND MURINE-HUMAN COMPARATIVE TRANSCRIPTOME ANALYSES IDENTIFY TARGETABLE GENES FOR HUMAN SYSTEMIC LUPUS ERYTHEMATOUS AND LUPUS NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
218	Response to: Correspondence on "Update on the diagnosis and management of systemic lupus erythematosus" by Zhou et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e192-e192.	0.5	0
219	Developing novel drugs for systemic lupus erythematosus. Lessons learned from the belimumab trials. <i>Reviews in Health Care</i> , 2012, 3, 209-222.	0.1	0
220	NIH Study of Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 1994, 121, 389.	2.0	0
221	Elevated Interleukin-10 and "Disappearing HDL Syndrome" in Lymphoproliferative Disorders. <i>Blood</i> , 2014, 124, 4134-4134.	0.6	0
222	Response to: "Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus" by Wu et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-217804.	0.5	0
223	Mitophagy Balance in Various Cell Subsets in Patients with ANCA-Associated Vasculitis and Correlation with the Presence of Anti-Neutrophil Cytoplasmic Antibodies. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 366.	0.3	0
224	Evolving Concepts in Systemic Lupus Erythematosus. <i>Israel Medical Association Journal</i> , 2016, 18, 749-753.	0.1	0
225	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. <i>Israel Medical Association Journal</i> , 2019, 21, 292-297.	0.1	0